Valuation: Theracryf Plc

Market Cap 5.66M 4.9M 4.6M 4.19M 7.88M 540M 8M 54.05M 21.13M 270M 21.25M 20.79M 901M P/E 2026 *
-1.32x
P/E 2027 * -1.62x
Enterprise Value 3.51M 3.04M 2.85M 2.6M 4.89M 335M 4.96M 33.51M 13.1M 168M 13.18M 12.89M 559M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 week-2.50%
1 month-9.30%
3 months-11.36%
6 months-7.14%
Current year-2.50%
1 week 0.19
Extreme 0.19
0.21
1 month 0.19
Extreme 0.19
0.22
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
2.88
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 30/09/2020
Director of Finance/CFO - 04/09/2023
Chief Tech/Sci/R&D Officer - 30/04/2021
Director TitleAgeSince
Director/Board Member - 13/10/2015
Director/Board Member 64 30/09/2020
Director/Board Member - 31/12/2023
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25 Others

Director

422,727,272 19.8499%
04/03/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.50%-13.33%-91.88% 5.66M
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
-0.02%+33.91%+8.69%+494.62% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.84%+1.18%-15.97%-13.19% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-1.61%-10.95%+33.04%+134.73% 12.72B
Average +0.01%+8.04%+51.17%+172.80% 26.67B
Weighted average by Cap. +0.11%+10.12%+56.25%+166.41%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.9M -2.72M -2.48M -4.66M -320M -4.74M -31.99M -12.51M -160M -12.58M -12.31M -534M -3.43M -2.97M -2.78M -2.54M -4.77M -327M -4.85M -32.74M -12.8M -164M -12.88M -12.6M -546M
Net Debt -2.15M -1.86M -1.75M -1.59M -2.99M -205M -3.04M -20.54M -8.03M -103M -8.08M -7.9M -343M 453K 393K 368K 336K 631K 43.25M 641K 4.33M 1.69M 21.66M 1.7M 1.67M 72.21M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
12/08/26 GBX 0.1950 0.00% 1,125,000
11/08/26 GBX 0.1950 -2.50% 10,361,975
10/08/26 GBX 0.2000 0.00% 818,014
07/08/26 GBX 0.2000 0.00% 439,961
06/08/26 GBX 0.2000 0.00% 0
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002634USD
Average target price
0.0431USD
Spread / Average Target
+1,537.64%

Annual profits - Rate of surprise